Study of parsaclisib plus ruxolitinib in myelofibrosis discontinued
Last Updated: Tuesday, April 11, 2023
The phase 3 LIMBER-304 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who had a previous suboptimal response to ruxolitinib alone has been discontinued, after a preplanned interim analysis determined that the trial was not expected to meet its primary endpoint of targeted reduction in spleen volume from baseline to week 24.
Advertisement
News & Literature Highlights